Development of radiogallium-labeled agents for PET imaging without cyclotron
| Project/Area Number |
21390347
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kobe Pharmaceutical University (2011)
Kyushu University (2009-2010) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAGATA Yasuhiro 浜松医科大学, 光量子医学研究センター, 教授 (20209399)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2011: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2010: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2009: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Keywords | 放射性医薬品 / 造影剤 / 放射線 / 癌 / 薬学 |
|---|
| Research Abstract |
In this study, we designed DOTA-MN2 and DOTA-TZ2, employing metronidazole moiety as a recognition site of hypoxic tumors and Ac-TZ14011 peptide as a CXCR4 ligand, respectively. Radiogallium-DOTA-MN2 exhibited the high stability and significant accumulation in the hypoxic tumors. Ga-DOTA-TZ2 showed the high affinity to CXCR4 in vitro. These results provide useful information about the chemical design of radiogallium-labeled radiopharmaceuticals for PET studies.
|
Report
(4 results)
Research Products
(11 results)
